Immunosuppressive and Immunomodulatory Drugs
Immune dysregulation underlies most complex chronic skin diseases, from common inflammatory conditions (atopic dermatitis, psoriasis) to life-threatening autoimmune blistering diseases (pemphigus, pemphigoid) and connective tissue diseases (lupus erythematosus, scleroderma, dermatomyositis). Systemic treatment with immunosuppressants and immunomodulators is often decisive in stopping flares, restoring immune balance and protecting the skin from runaway autoimmune attack.
Both groups share the same clinical goal of controlling skin disease, but they work differently. Immunosuppressants (such as cyclosporine and mycophenolate) dampen the immune response broadly, whereas immunomodulators (such as dapsone, biologics and JAK inhibitors) adjust and rebalance specific cytokine axes or intracellular signaling pathways without suppressing the immune system as a whole.
At Haute-Derma, using these drugs requires careful screening for hidden infections, monitoring of the target organs (liver, kidneys, bone marrow) and a planned down-titration strategy, so that patients get the best possible results while staying safe over the long term.
Mechanisms of Action and Pharmacodynamics
Systemic Immunosuppressants
These drugs interrupt the proliferation and activation of key immune cell lines:
- Calcineurin inhibitors (cyclosporine A, tacrolimus): cyclosporine A binds cyclophilin, while tacrolimus binds FKBP-12. The resulting complex blocks the phosphatase calcineurin, so the transcription factor NFAT (nuclear factor of activated T cells) is not dephosphorylated. As a result, the interleukin-2 (IL-2) gene is not transcribed and T-cell proliferation and activation are shut down.
- S-phase and nucleotide synthesis inhibitors (mycophenolate mofetil, azathioprine, methotrexate): these block purine/pyrimidine or folate synthesis, preventing activated T and B lymphocytes from dividing and so reducing the production of autoantibodies.
Immunomodulators
Rather than weakening the whole immune system, these drugs redirect the immune response:
- Intracellular signaling inhibitors (JAK-STAT inhibitors: upadacitinib, baricitinib): these compete for the ATP-binding site on the Janus kinases (JAK1, JAK2, JAK3, TYK2), blocking the signals that many pro-inflammatory cytokines (IL-4, IL-13, IL-31, IFN-γ) send from the cell surface to the nucleus.
- Neutrophil and chemotaxis modulators (dapsone, colchicine): dapsone inhibits the enzyme myeloperoxidase (MPO) and stops neutrophils from migrating into the skin, which makes it very effective in pustular skin diseases and IgA-mediated blistering disease.
- Key cytokine targeting (biologics: dupilumab, secukinumab): monoclonal antibodies bind selectively to a specific receptor or cytokine (such as IL-4Rα, IL-17A or IL-23), precisely disabling the core inflammatory link of the Th2 or Th17 response.
Clinical Drug Classes
- Calcineurin inhibitors: cyclosporine A (oral), tacrolimus (oral/topical). They act very quickly, making them ideal "bridging therapy" for severe flares of atopic dermatitis or psoriasis.
- Lymphocyte-suppressing antimetabolites: mycophenolate mofetil (MMF), azathioprine. First-line long-term options for pemphigus vulgaris, bullous pemphigoid and cutaneous lupus erythematosus.
- Classic immunomodulators: dapsone, colchicine. Preferred for linear IgA bullous dermatosis, necrotizing vasculitis and pyoderma gangrenosum.
- Molecular targeted therapy:
- JAK inhibitors: upadacitinib, baricitinib, abrocitinib (for moderate-to-severe atopic dermatitis and alopecia areata).
- Biologics: dupilumab (anti-IL-4/13), secukinumab/ixekizumab (anti-IL-17A), guselkumab (anti-IL-23).
Managing Toxicity and Clinical Safety
- Kidney toxicity and high blood pressure (cyclosporine A): cyclosporine constricts the afferent arterioles of the kidney, lowering the glomerular filtration rate (eGFR), and can cause interstitial fibrosis with prolonged use (more than 1 year). Blood pressure and serum creatinine must be checked every 2 weeks during the first month.
- Screening for opportunistic infections and viral reactivation: every patient about to start a potent immunosuppressant or JAK inhibitor is at risk of reactivating latent tuberculosis, hepatitis B/C and herpes zoster.
- Risk of venous thrombosis and cardiovascular events (JAK inhibitors): JAK inhibitors should be prescribed with caution to patients over 65, long-term smokers and people at risk of venous thromboembolism (VTE).
- Hemolytic anemia and methemoglobinemia (dapsone): dapsone puts oxidative stress on red blood cells. Patients with G6PD deficiency risk severe acute hemolysis, so G6PD activity must be measured before prescribing.
Treatment and Monitoring Protocol at Haute-Derma
Pre-Treatment Baseline Screening
- Complete blood count (CBC), platelet and reticulocyte counts.
- Blood chemistry: kidney function (creatinine, urea, eGFR), liver function (AST, ALT, bilirubin), lipid panel and electrolytes.
- Infection screening: QuantiFERON-TB Gold (or Mantoux test), HBsAg, anti-HBc, anti-HCV and HIV.
- G6PD enzyme level (mandatory if dapsone is planned).
- A negative pregnancy test for women of childbearing age.
Starting Treatment and Individualizing the Dose
- Cyclosporine A: start at 3–5 mg/kg/day in 2 divided doses. Once the disease is controlled (usually after 2–6 weeks), reduce by 0.5 mg/kg/day every 2 weeks.
- Mycophenolate mofetil: start at 1–2 g/day, increasing to 2.5–3 g/day if the blistering disease progresses.
- Upadacitinib: standard dose of 15 mg or 30 mg once daily, depending on the severity of atopic dermatitis.
Monitoring Schedule and Down-Titration Strategy
- Blood pressure, creatinine and liver enzymes every 2 weeks in the first month, then monthly.
- Stop cyclosporine if creatinine rises more than 30% above baseline or systolic blood pressure stays above 140 mmHg despite adjusting antihypertensive treatment.
- Plan the switch to a safer maintenance drug (such as MMF or dupilumab) once cyclosporine has brought the flare under control.
